Purchase this article with an account.
K. Ikeda, S. Mizunoya, Y. Kanaya, H. Kanai, A. Hosoda, H. Abe, H. Kidahashi, M. Suzuki; Clinical and Electrophysiological Evaluation Following Intravitreal Bevacizumab for Macular Edema Secondary to Branch Retinal Vein Occlusion. Invest. Ophthalmol. Vis. Sci. 2008;49(13):2712.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To determine the efficacy of intravitreal bevacizumab injection in patients with macular edema (ME) secondary to branch retinal vein occlusion (BRVO).
Nine consecutive patients with macular edema secondary to BRVO received an intravitreal injection of 1.25mg/0.05ml bevacizumab. Patients had a complete ophthalmic evaluation including visual acuity testing, optical coherence tomography (OCT), fluroscein angiography, electroretinography (ERG), and pattern reversal visual evoked potential (VEP) at baseline and at follow-up visits.
The follow-up period was >2 months. The mean best-corrected visual acuity in logMAR units improved from 0.93 at baseline to 0.50, 0.55 at 1 and 2 months. The mean foveal thickness was 651 µm at baseline and decreased to 461, 342, 295, and 428 µm at 1 day, 1 week, 1 month, and 2 months (P <0.01). The mean amplitudes and implicit times of the a- and b-waves of the ERGs were not significantly changed 2 weeks after the injection compared to the baseline values. The amplitudes and latencies of P100 of the VEPs were not significantly changed at 2 weeks. No adverse side effects were observed following the injection.
An intravitreal injection of bevacizumab results in significant short-term improvement of visual acuity and macular edema secondary to BRVO. No ocular toxicity or adverse effects were observed by clinical and electrophysiological examinations.
This PDF is available to Subscribers Only